Browse Category

NASDAQ:RYTM News 11 December 2025 - 30 December 2025

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise built around its melanocortin‑4 receptor (MC4R) agonist, IMCIVREE (setmelanotide).Investing.com+1 As of Thursday morning, RYTM was trading around $121 per share, up more than 15% on the day according to real‑time data from MarketBeat, and roughly 80–90% higher year‑to‑date.MarketBeat+2Investing.com+2 For a mid‑cap biotech that is still loss‑making, that kind of move demands a closer look at what changed, what analysts expect
11 December 2025

Stock Market Today

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Lam Research stock price jumps 8% as chip rally returns — what to watch next week

Lam Research stock price jumps 8% as chip rally returns — what to watch next week

7 February 2026
Lam Research shares surged 8.3% to $231.01 Friday, with after-hours trading flat. The move followed a broad rally in chip stocks, pushing the PHLX semiconductor index up 5.7% as Nvidia, AMD, and Broadcom advanced. Lam announced a $0.26 quarterly dividend and a senior executive exercised 53,925 shares. Investors await U.S. jobs and inflation data next week.
Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

7 February 2026
Goldman Sachs shares jumped 4.3% to $928.75 Friday after confirming it is working with AI startup Anthropic on internal “AI agents.” The stock’s rally helped lift the Dow above 50,000 for the first time. Delayed U.S. jobs and inflation data are due midweek and could affect rate expectations. Goldman also filed for new structured notes tied to the Russell 2000 and S&P 500.
Go toTop